Share this page:
A FREE Live Webcast on May 14
During a live webcast on Wednesday, May 14 from 7 to 7:30 p.m., Christopher Kalhorn, MD, andFernando Pagan, MD, will be available to answer your questions about movement disorders, and their medical management, treatment, evaluation and surgical options, including deep brain stimulation, (DBS).
May 13, 2014
Category : Neurosciences ,
Back to Top
Related News
Study: Cancer Drug Restores Important Brain Dopamine in Parkinson’s Patients
A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson’s disease or dementia with Lewy bodies.
Category : Cancer , Innovation , MedStar in the community , Neurosciences , Oncology ,
Georgetown Seeks Volunteers for New Immunotherapy Clinical Trial for Alzheimer’s
The Memory Disorders Program at Georgetown University is seeking volunteers to participate in an international clinical trial of a drug that, in an early phase study, has demonstrated promise in slowing mental decline in Alzheimer’s disease.
Category : Neurosciences , Research ,
Huntington Disease Center at Georgetown Designated As Center of Excellence
The Huntington’s Disease Society of America (HDSA) has designated the Huntington Disease Care, Education and Research Center at Georgetown as an HDSA Center of Excellence for 2016.
Category : Neurosciences ,
Georgetown Hosts Research Summit on Concussions in Females
Georgetown University Medical Center will host the first summit to explore gender differences of female brain injuries
Category : Neurosciences , Research , Women’s services ,
Cancer Drug Improved Cognition and Motor Skills in Small Parkinson’s Clinical Trial
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small phase I clinical trial, report researchers at Georgetown University Medical Center (GUMC) in Washington.
Category : Cancer , Neurosciences ,
Resveratrol Impacts Alzheimer’s Disease Biomarker
The largest nationwide clinical trial to study high-dose resveratrol long-term in people with mild to moderate Alzheimer’s disease found that a biomarker that declines when the disease progresses was stabilized in people who took the purified form of resveratrol.
Category : Neurosciences ,
Ira Shoulson Honored for His “Tireless” Advocacy on Behalf of Patients with Neurological Disorders, including Parkinson’s Disease and Huntington Disease
The American Academy of Neurology honored Ira Shoulson, MD, with its 2015 patient advocacy of the year award citing his “passion, dedication and enthusiasm.”
Category : Neurosciences ,
